DELRAY BEACH, Fla., April 2, 2026 /PRNewswire/ -- PanGIA Biotech, Inc. ("PanGIA") announced a peer-reviewed clinical study published in Diagnostics, "Urine-Based Machine Learning Assay Detects ...
The study's testing accurately identified prostate cancer 91% of the time and accurately ruled out men without prostate cancer 84% of the time. A urine-based biomarker panel may be a promising, ...
The newly developed urine test helps identify which prostate cancer patients need a biopsy and which can safely skip the ...
Screening for prostate cancer becomes more complex in men over the age of 70. The US Preventive Services Task Force (USPSTF) currently recommends against routine PSA testing in this age group. The PSA ...
Screening for prostate cancer using a blood test likely reduces the risk of dying from prostate cancer and may also reduce the risk of dying from any cause. Screening likely makes little to no ...
The FDA approved Cleveland Diagnostics' blood-based test to help diagnose high-grade prostate tumors and aid in biopsy decisions, the company announced. Dubbed IsoPSA, the in vitro diagnostic kit is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results